Skip to main content
. 2007 May 4;133(9):653–661. doi: 10.1007/s00432-007-0216-y

Table 3.

Disease pattern, response, and outcome of trial patients

Number Pre-treatment Disease pattern at TCE start Status after two cycles Best response Best response confirmed by Final outcome
1 NB97 HR BM, bone, LN PD PD Clinical DOD
2 NB97 HR PT, BM PR PR CT, BM DOD
3 NB97 HR PT, liver, LN n.a. PR Ultrasound DOD
4 NB97 HR PT PR PR MRI Relapse
5 NB97 SR PT SD PR MRI, MIBG Progression
6 NB97 HR PT, BM, bone PD PD MRI, BM DOD
7 NB97 HR PT, BM, bone PR PR MRI, MIBG DOD
8 NB97 HR PT, BM, bone PD PD MRI, MIBG DOD
9 NB90 HR Bone, pleura, liver n.a. SD MRI, MIBG SMD
10 NB97 HR BM PR PR MIBG, BM DOD
11 NB97 SR PT VGPR VGPR MRI, MIBG DOD
12 NB97 SR PT PR PR MRI CR2
13 NB90 HR BM, bone PD PD BM CR2
14 NB97 HR PT, BM, bone, liver PD PD MRI DOD
15 NB97 HR Bone PR CR MRI, MIBG, bone scan CR2
16 NB97 HR PT, BM PR PR MRI, BM DOD
17 NB97 HR PT PR PR MRI DOD
18 NB97 HR CNS PR PR CCT DOD
19 NB97 SR BM, bone PR PR MRI, BM Progression
20 NB97 SR PT, BM, bone PD PD MRI CR3
21 NB97 HR BM n.a. PR MIBG, BM PR
22 NB97 SR PT c.r. c.r. MRI CR3
23 NB97 HR PT, BM, bone PR PR MRI, MIBG, BM DOD
24 NB97 HR BM PD PD MRI, clinical DOD
25 NB97 HR Bone PR PR MIBG, MRI DOD
26 NB97 HR PT PR CR MRI DOD
27 NB90 HR + six cycles carboplatin/VP16 LN PR VGPR MRI CR3
28 NB97 HR PT PD PD MRI DOD
29 NB97 HR BM, bone n.a. PR MIBG, BM PR
30 NB97 HR BM, CNS PD PD MRI, clinical Progression
31 NB97 HR PT, BM, bone PD PD Clinical PR
32 NB97 SR PT (MIBG negative) c.r. c.r. MRI CR2
33 NB97 HR PT, liver PD PD MRI DOD
34 None PT, bone PR MRI CR2
35 None PT, BM, bone PR MRI, MIBG, BM Progression
36 None PT, BM, bone PR MRI, MIBG, BM DOD
37 None PT, LN, pleura PR MRI Progression
38 None PT, BM, bone SD Ultrasound, MIBG, BM DOD
39 None PT, BM PR Ultrasound, BM DOD
40 None PT, bone, LN PR MRI, MIBG CR1
41 None PT, bone, liver SD MRI, BM CR1
42 None PT, BM, bone PR MRI, MIBG, BM DOD
43 None PT, bone PR MRI CR1
44 None PT, BM, bone PD MRI, MIBG CR2

PT primary tumor, BM bone marrow, LN distant lymph node, n.a. not assessed, c.r. complete resection, DOD death of disease, SMD secondary malignant disease